Bone Marrow Endothelial Progenitors Augment Atherosclerotic Plaque Regression in a Mouse Model of Plasma Lipid Lowering
Open Access
- 18 October 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 30 (12) , 2720-2731
Abstract
The major event initiating atherosclerosis is hypercholesterolemia-induced disruption of vascular endothelium integrity. In settings of endothelial damage, endothelial progenitor cells (EPCs) are mobilized from bone marrow into circulation and home to sites of vascular injury where they aid endothelial regeneration. Given the beneficial effects of EPCs in vascular repair, we hypothesized that these cells play a pivotal role in atherosclerosis regression. We tested our hypothesis in the atherosclerosis-prone mouse model in which hypercholesterolemia, one of the main factors affecting EPC homeostasis, is reversible (Reversa mice). In these mice, normalization of plasma lipids decreased atherosclerotic burden; however, plaque regression was incomplete. To explore whether endothelial progenitors contribute to atherosclerosis regression, bone marrow EPCs from a transgenic strain expressing green fluorescent protein (GFP) under the control of endothelial cell-specific Tie2 promoter (Tie2-GFP+) were isolated. These cells were then adoptively transferred into atheroregressing Reversa recipients where they augmented plaque regression induced by reversal of hypercholesterolemia. Advanced plaque regression correlated with engraftment of Tie2-GFP+ EPCs into endothelium and resulted in an increase in atheroprotective nitric oxide and improved vascular relaxation. Similarly augmented plaque regression was also detected in regressing Reversa mice treated with the stem cell mobilizer AMD3100 which also mobilizes EPCs to peripheral blood. We conclude that correction of hypercholesterolemia in Reversa mice leads to partial plaque regression that can be augmented by AMD3100 treatment or by adoptive transfer of EPCs. This suggests that direct cell therapy or indirect progenitor cell mobilization therapy may be used in combination with statins to treat atherosclerosis. STEM CELLS 2012;30:2720–2731Keywords
This publication has 67 references indexed in Scilit:
- Effect of Two Intensive Statin Regimens on Progression of Coronary DiseaseNew England Journal of Medicine, 2011
- Homing of Progenitor Cells to Ischemic TissuesAntioxidants & Redox Signaling, 2011
- Reversal of Hyperlipidemia With a Genetic Switch Favorably Affects the Content and Inflammatory State of Macrophages in Atherosclerotic PlaquesCirculation, 2011
- CXCR4 blockade augments bone marrow progenitor cell recruitment to the neovasculature and reduces mortality after myocardial infarctionProceedings of the National Academy of Sciences, 2010
- Endothelial progenitor cells: what use for the cardiologist?Journal of Angiogenesis Research, 2010
- Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100Blood, 2006
- G-CSF and AMD3100 mobilize monocytes into the blood that stimulate angiogenesis in vivo through a paracrine mechanismBlood, 2006
- Vascular endothelial growth factor-A induces plaque expansion in ApoE knock-out mice by promoting de novo leukocyte recruitmentBlood, 2006
- Functional disruption of α4 integrin mobilizes bone marrow–derived endothelial progenitors and augments ischemic neovascularizationJournal of Experimental Medicine, 2006
- Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularizationJournal of Clinical Investigation, 1999